Unveiling the Impact of Transparency in Coverage Data on Healthcare Prices

By HEOR Staff Writer

October 30, 2023

The Role of Transparency in Coverage Data

In the realm of healthcare, the importance of transparency cannot be overstated. A recent study by Benjamin L. Chartock, PhD; Kosali Simon, PhD; Christopher M. Whaley, PhD, has shed light on how transparency in coverage (TiC) data can significantly influence prices for common healthcare services. The researchers examined TiC price data from Humana, a major national insurer in the USA, highlighting the potential uses of such data for future research.

Unravelling Price Variation

The study’s findings revealed substantial price variation for common healthcare services. The researchers focused on seven procedures, including both ‘shoppable’ and ‘non-shoppable’ services. Interestingly, the variation in prices for these services was similar, regardless of their ‘shoppability’. The study also noted that mean county-level prices were lowest in the central US and Florida, with higher prices observed in the upper-Midwest and Southeast.

The findings of the study make a compelling case for the necessity of further research into the factors that drive price variation in healthcare. The topic of whether or not these prices accurately reflect worth, or whether or not they are an indication of inequalities in market power and negotiation leverage, will need to be investigated more in the future. If the second possibility is correct, then there is an even greater requirement for regulations that guarantee competitive healthcare markets.

In conclusion, the study highlights the potential of informed healthcare consumerism as a lever for managing costs and enhancing patient happiness. It also opens up new possibilities for the use of TiC data in larger settings, which opens up new avenues for using TiC data.

Reference url

Recent Posts

Ozempic Public Funding Approval in Portugal: Key Insights and Implications

By HEOR Staff Writer

February 3, 2026

Ozempic public funding is now approved in Portugal for specific adults with type 2 diabetes. Infarmed's recent decision reimburses semaglutide (Ozempic) through the National Health Service (SNS). It targets those with inadequately controlled type 2 diabetes, BMI ≥30 kg/m², or high cardiovascular ...
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies

By João L. Carapinha

February 2, 2026

CHMP January 2026 Approvals Signal Expanded Access to Innovative Therapies The CH...
Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained

By HEOR Staff Writer

January 27, 2026

On December 9, 2025, the Board of Directors of Zorginstituut Nederland (decision reference 2025027072) approved amendments to the Beleidsregels risicoverevening for 2022, 2023, 2024, and 2025. These changes, published in Staatscourant 2026 nr. 967 on January 19, 2026, correct te...